Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.

TL;DR

A 60-person randomized controlled trial found that CoQ10 supplementation during paclitaxel chemotherapy reduced peripheral neuropathy incidence from 96% to 68% and delayed its onset, while also improving fatigue, insomnia, and cardiac function markers.

What the Study Found

Paclitaxel remains one of the most effective chemotherapy drugs for breast cancer, but its cumulative toxicity profile limits treatment tolerability. The drug damages mitochondrial function and increases oxidative stress, leading to peripheral neuropathy, fatigue, cardiac dysfunction, and gastrointestinal symptoms that can force dose reductions or treatment discontinuation. This randomized controlled trial tested whether CoQ10, a mitochondrial electron transport cofactor, could mitigate these harms.

The research enrolled 60 breast cancer patients receiving weekly paclitaxel (80 mg/m²) for 12 weeks. Thirty patients received paclitaxel alone (control), while 30 received paclitaxel plus oral CoQ10 supplementation. Researchers used standardized toxicity grading (CTCAE version 5.0) to track adverse events across multiple body systems, with peripheral neuropathy as the primary outcome.

CoQ10 supplementation produced a clinically meaningful reduction in grade 2 or higher peripheral neuropathy: 68% of the CoQ10 group experienced this toxicity versus 96% of controls (p = 0.01). Beyond incidence, the supplement delayed neuropathy onset substantially, with median time-to-onset of 30 days in the CoQ10 group compared to 20 days in controls (log-rank p = 0.005). This 10-day delay extends the window for completing chemotherapy before dose-limiting toxicity develops. Secondary endpoints showed significant benefits across multiple toxicities from week 9 onward: fatigue and insomnia both improved with CoQ10, as did mucositis, diarrhea, arthralgia, and myalgia from week 11 forward (p < 0.05). Hemoglobin levels were higher in the CoQ10 group at week 12 (p = 0.009), suggesting reduced chemotherapy-induced anemia. Critically, left ventricular ejection fraction (a marker of cardiac function) was preserved in the CoQ10 group compared to controls (p = 0.005), addressing a known long-term toxicity of paclitaxel.

The trial was open-label (unblinded), which introduces potential bias, though the use of objective outcome measures (CTCAE grading, hemoglobin values, ejection fraction) reduces subjective interpretation. The CoQ10 dose and formulation were not specified in the abstract, limiting reproducibility. The 12-week observation period captured acute and early cumulative toxicities but does not address long-term neuropathy recovery or cardiac outcomes beyond the treatment window.

What This Means for You

For breast cancer patients receiving paclitaxel chemotherapy, these findings suggest CoQ10 supplementation may be worth discussing with your oncology team as an adjunctive strategy. The magnitude of neuropathy reduction (28 percentage points lower incidence) and the 10-day delay in symptom onset both have practical significance: peripheral neuropathy is often the dose-limiting toxicity that forces treatment interruptions or dose reductions. Delaying its onset could allow completion of planned chemotherapy regimens.

The cardiac preservation signal is particularly noteworthy, as paclitaxel-induced cardiomyopathy is a serious long-term consequence. While this trial is too small and short to establish prevention of major cardiac events, the change in ejection fraction is encouraging enough to warrant further investigation in larger trials with extended follow-up.

The most appropriate timing and dose of CoQ10 remain unclear from this single trial. Standard ubiquinone or ubiquinol formulations (the two major forms) have different bioavailability profiles. Pairing CoQ10 with fat-containing meals improves absorption. Dosing in supplement studies typically ranges from 100-600 mg daily, though the abstract does not specify what dose was used here.

This evidence is not strong enough to claim CoQ10 "prevents" chemotherapy toxicity, but it does suggest that supplementation during paclitaxel treatment is associated with measurable reductions in several harms. Conversation with your oncologist is essential before starting any supplement, as some compounds interact with chemotherapy metabolism or may interfere with treatment efficacy.

Sources

Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial. BMC Pharmacology and Toxicology. PubMed ID: 42401951